 |
Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 |
|---|---|
| Trade Name | Kymriah (Tisagenlecleucel) |
| Orphan Indication | Acute lymphoblastic leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2014-01-31 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 |
Related Access Program
Novartis Pharmaceuticals – Acute Lymphoblastic Leukemia
University of California, San Francisco – Acute Lymphoblastic Leukemia
ERYtech Pharma – Acute Lymphoblastic Leukemia
University of California, San Francisco – Acute lymphoblastic leukemia
ERYtech Pharma – Acute lymphoblastic leukemia
Amgen – Acute lymphoblastic leukemia